Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 260.50 INR
Change Today 0.00 / 0.00%
Volume 0.0
SVLS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

suven life sciences ltd (SVLS) Snapshot

Open
265.80
Previous Close
264.20
Day High
266.35
Day Low
257.50
52 Week High
04/15/15 - 338.50
52 Week Low
08/13/14 - 112.10
Market Cap
33.2B
Average Volume 10 Days
565.1K
EPS TTM
0.72
Shares Outstanding
127.3M
EX-Date
07/23/15
P/E TM
360.2x
Dividend
0.60
Dividend Yield
0.23%
Current Stock Chart for SUVEN LIFE SCIENCES LTD (SVLS)

Related News

No related news articles were found.

suven life sciences ltd (SVLS) Related Businessweek News

No Related Businessweek News Found

suven life sciences ltd (SVLS) Details

Suven Life Sciences Limited, a biopharmaceutical company, designs, manufactures, and supplies bulk actives, drug intermediates, and fine chemicals for the life science industry worldwide. It provides advanced intermediates, intermediates, active pharmaceutical ingredients, and stock chemicals. The company also offers contract research and manufacturing services, including development and supply of pharmaceutical and agro chemical intermediates for new chemical entities. In addition, it provides discovery and development of new chemical entities for CNS disorders; research collaborative projects with pharmaceutical companies; and drug discovery research services, such as in-vitro screening and molecular biology, drug metabolism and pharmacokinetics, pharmacology, toxicology, and bioanalysis, as well as operates a formulation development center. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. Suven Life Sciences Limited was founded in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

881 Employees
Last Reported Date: 05/26/15
Founded in 1989

suven life sciences ltd (SVLS) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: 14.5M
Whole-Time Director, Member of Share Transfer...
Total Annual Compensation: 6.9M
Compensation as of Fiscal Year 2015.

suven life sciences ltd (SVLS) Key Developments

Suven Life Sciences Limited Proposes Dividend for the Fiscal Year 2015, Payable on and from August 28, 2015

Suven Life Sciences Limited announced that its Board has proposed a Dividend of INR 0.60 per share (60% of face value INR 1.00 each) for the financial year 2014-15, subject To Approve the shareholders in the ensuing annual general meeting. The dividend will be paid on and from 28th August, 2015 to the members as on book closure date, subject to the approval of Members in the ensuing Annual General Meeting.

Suven Life Sciences Limited Reports Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Suven Life Sciences Limited reported audited earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company reported revenue of INR 1,145 million against INR 1,320 million, down by 13%, profit after tax was INR 169 million against INR 324 million, down by 48% and EBITDA was INR 265 million against INR 486 million, down by 45%. Total income from operations were INR 1,106.625 million against INR 1,308.034 million a year ago. Profit from operations before other income finance costs and exceptional items were INR 220.518 million against INR 451.618 million a year ago. Profit from ordinary activities before tax was INR 226.485 million against INR 446.696 million a year ago. Basic and diluted share before extraordinary items were INR 1.41 against INR 2.77 per share a year ago. For the year, the company reported revenue of INR 5,294 million against INR 5,133 million, up by 3%, profit after tax was INR 1,088 million against INR 1,442 million, down by 25% and EBITDA was INR 1,680 million against INR 2,221 million, down by 24%. Total income from operations were INR 5,208.55 million against INR 5,103.124 million a year ago. Profit from operations before other income finance costs and exceptional items were INR 1,593.334 million against INR 2,102.212 million a year ago. Profit from ordinary activities before tax was INR 1,515.547 million against INR 2,027.379 million a year ago. Basic and diluted share before extraordinary items were INR 9.04 against INR 12.34 per share a year ago.

Suven Life Sciences Limited, 2015 Earnings Call, May 27, 2015

Suven Life Sciences Limited, 2015 Earnings Call, May 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVLS:IN 260.50 INR 0.00

SVLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVLS.
View Industry Companies
 

Industry Analysis

SVLS

Industry Average

Valuation SVLS Industry Range
Price/Earnings 27.9x
Price/Sales 5.8x
Price/Book 5.7x
Price/Cash Flow 26.6x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUVEN LIFE SCIENCES LTD, please visit www.suven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.